NeuBase Therapeutics, Inc. (NBSE) Financials
Stock symbol NBSE is outdated, potentially delisted? Maybe it is available on other exchange?
NBSE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2023 | 18.6 million | 9.5 million |
| June 30, 2023 | 22.3 million | 11.1 million |
| March 31, 2023 | 21.5 million | 7.0 million |
| Dec. 31, 2022 | 25.6 million | 7.4 million |
NBSE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2023 | -2.0 million | -292343 |
| June 30, 2023 | -3.6 million | 245012 |
| March 31, 2023 | -3.5 million | 316689 |
| Dec. 31, 2022 | -5.7 million | -509072 |
NBSE Net Income
No data available :(
NBSE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2023 | 12.6 million | - | 5.3 million |
| June 30, 2023 | 14.7 million | - | 5.5 million |
| March 31, 2023 | 13.8 million | - | 5.6 million |
| Dec. 31, 2022 | 17.4 million | - | 5.8 million |
NBSE Shares Outstanding
NBSE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2023 | - | 387564 | 1.2 million | - |
| June 30, 2023 | 6 | 1.3 million | 2.4 million | - |
| March 31, 2023 | 13447 | 1.2 million | 2.9 million | - |
| Dec. 31, 2022 | 49844 | 1.4 million | 2.6 million | - |
NBSE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2023 | - | 250246 |
| June 30, 2023 | - | 303975 |
| March 31, 2023 | - | 300473 |
| Dec. 31, 2022 | - | - |
NBSE
Price: $0.38
52 week price:
Earnings Per Share: -18.60 USD
P/E Ratio: -0.04
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 97523
Market Capitalization: 1.4 million